MassGeneral Institute for Neurodegenerative Disease

Translating today's discoveries into tomorrow's cures

Facebook icon Twitter Icon

Goosens, Ki Ann, PhD

Biography
Affiliations

Ki Goosens seeks to understand how chronic stress changes the brain and makes people more susceptible to emotional disorders and other diseases. It’s known that chronic stress significantly increases the risk of psychiatric disease, such as post-traumatic stress disorder (PTSD) and major depressive disorder, as well as memory problems and Alzheimer’s disease. In studies that employ animal models and human subjects, Goosens takes a systems-level approach to unraveling the multifaceted effects of chronic stress in brain circuits that regulate emotional learning and memory.

Arnold, Steven E., MD

Biography
Affiliations

Dr. Arnold leads a broad clinical and translational research program on Alzheimer’s disease and other neurocognitive disorders of aging. His major interests include clinicopathological correlation studies of molecular markers in human cerebrospinal fluid and postmortem brain tissue, the discovery and validation of biochemical biomarkers for diagnosis and staging of neurodegenerative dementias, and the design and conduct of novel, early phase and proof-of-concept clinical trials.

Lagier-Tourenne, Clotilde, MD, PhD

Biography
Affiliations

Clotilde Lagier-Tourenne performs patient-oriented research to understand the molecular mechanisms driving neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and to develop therapeutic strategies. Mutations and/or cellular mislocalization of several RNA binding proteins have been identified as central components in the pathogenesis of ALS and FTD. Using innovative cellular and genomics techniques, Lagier-Tourenne’s group explores the regulatory networks between RNA binding proteins and changes in RNA expression that occur in these diseases.

Moir, Robert, PhD

Biography
Affiliations

Robert Moir’s research focuses on the biochemical and cellular mechanisms of neurodegeneration in Alzheimer's disease (AD) and aging. His work has uncovered new therapeutic targets aimed at preventing the accumulation of beta-amyloid (Aβ), the primary neurotoxic agent in AD. Moir was the first to identify the low-density lipoprotein receptor protein (LRP) as the mediator of an important early step in Aβ production in the brain. Today, LRP-mediated Aβ clearance pathways are increasingly recognized as major targets for therapeutic intervention.

Zhang, Can (Martin), MD, PhD

Biography
Affiliations

Can (Martin) Zhang’s research is focused on identifying the mechanism of neurodegeneration in Alzheimer’s disease (AD), with the goal of identifying molecular targets and biomarkers that will translate into the development of novel therapeutic strategies for AD. The pathogenesis of AD is believed to be primarily driven by amyloid-B (AB), the principal component of senile plaques in the brain.

Sharma, Nutan, MD, PhD

Biography
Affiliations

Nutan Sharma combines clinical expertise in movement disorders with research into the genetics and pathophysiology of dystonia. As founder and director of the dystonia clinic at MGH, Dr. Sharma conducts systematic clinical evaluation of patients in a longitudinal study of the natural history of dystonia. She collaborates with MIND geneticists to identify new dystonia-causing genes, by collecting families with dystonia for careful clinical characterization and DNA analysis. To facilitate laboratory studies of dystonia mechanisms, Dr.

Pages